Home
Clinical Trials
Partnerships
Contact Us
News & Resources
Careers
About Us
Management Team
Board of Directors
Scientific and Clinical Advisory Boards
Commercial Advisory Board
Our Focus
Infectious Disease
Oncology
Our Product
Our Pipeline
Prophylactic
Therapeutic
Clinical Trials
Publications
Early/Expanded Access Policy
Our Science
Investors
Press Releases
Events and Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
About Us
Management Team
Board of Directors
Scientific and Clinical Advisory Boards
Commercial Advisory Board
Our Focus
Infectious Diseases
Oncology
Our Pipeline
Prophylactic
Therapeutic
Clinical Trials
Publications
Early/Expanded Access Policy
Our Product
Our Science and Technology
News and Resources
News
Posters
Publications
Videos
Investors
Press Releases
Company Information
Corporate Governance
Events and Presentations
SEC Filings
Stock Information
Careers
Partnerships
Contact Us
Search our website
Publications
Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
February 8th, 2021
Autologous T-cell Therapy for Cytomegalovirus as a Consolidative Treatment for Recurrent Glioblastoma
February 8th, 2021
Three decades of hepatitis B control with vaccination
February 8th, 2021
Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine
February 8th, 2021
Randomized Controlled Study Investigating Viral Suppression and Serological Response following Pre-S1/Pre-S2/S Vaccine Therapy Combined with Lamivudine Treatment in HBeAg-Positive Patients with Chronic Hepatitis B
February 8th, 2021
Enveloped Virus-Like Particle Expression of Human Cytomegalovirus Glycoprotein B Antigen Induces Antibodies with Potent and Broad Neutralizing Activity
February 8th, 2021
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
February 8th, 2021
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
February 8th, 2021
Rapid and high seroprotection rates achieved with a tri-antigenic hepatitis B vaccine in healthy young adults: Results from a Phase IV Study
February 8th, 2021
Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI
Sign Up Now